Curium and Lantheus announce a definitive agreement under which Curium would merge with Lantheus, combining Curium’s theranostics portfolio and global manufacturing platform with Lantheus’ complementary U.S. radiodiagnostics business. The transaction is structured as a cash deal for Lantheus shareholders. Financial Post reports that Lantheus shareholders receive cash consideration of up to $114.50 per share. The total transaction value is reported as up to $8.0 billion, representing a premium of 38% compared with Lantheus’ unaffected 60-day volume-weighted average price. The Yahoo Finance item likewise frames the transaction as Curium deepening its radiopharmaceuticals position through a deal valued at up to $8 billion. The coverage across sources centers on the combination of product and manufacturing capabilities and the reported per-share price and overall deal size. Additional details such as timing, regulatory approvals, and closing conditions are not included in the excerpts provided.